rosiglitazone + insulin

**Rosiglitazone + insulin** is a combination therapy used in diabetes management, most commonly in type 2 diabetes, though it has been studied in type 1 diabetes as well. Rosiglitazone is a thiazolidinedione (TZD) that acts as a selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity primarily in adipose tissue, skeletal muscle, and the liver. Insulin is a hormone therapy that replaces or supplements endogenous insulin to lower blood glucose by promoting cellular glucose uptake, primarily in muscle and fat tissue, and inhibiting hepatic glucose production. The combination is used where monotherapy is insufficient for glycemic control; however, the use of rosiglitazone with insulin can increase risks such as fluid retention and congestive heart failure. This combination is not standard first-line therapy and should be considered with caution due to safety concerns[2][6].